Drug Discovery

Target-based understanding of the termination of the AMG 794 clinical trial — a deep dive with spatial transcriptomics

Why did AMG 794 stop, and what does spatial transcriptomics tell us about the target landscape? A deep dive into the clinical trial termination through the lens of tissue-level biology.

Daeseung Lee December 1, 2025 - 8 min read

Spatial transcriptomics analysis of the AMG 794 target landscape

This article is republished from the Portrai Medium blog. For the full piece with figures, please read the original.

Read on Medium: Target-based understanding of the termination of the AMG 794 clinical trial — A deep dive with spatial transcriptomics

Target-based understanding of the termination of the AMG 794 clinical trial — a deep dive with spatial transcriptomics

Recommended reads

Mapping drug distribution at single-cell resolution

Unlocking the full potential of bispecific antibodies with PortraiTARGET™ POR-PBPK

Designing VGL — a multimodal foundation model for cancer cell biology

Benchmarking spatial transcriptomics models — what we measure, and why

Engineering a precision-glycosylated clickable albumin nanoplatform

AACR 2025 — Portrai abstracts

Weekly data spotlight — cost-effective single-cell analysis through spatial transcriptomics

Spatial transcriptomics reveals spatially diverse cancer-associated fibroblasts in lung squamous cell carcinoma linked to tumor progression

Analysis of unmapped RNA-seq data from cancer spatial transcriptome to decipher cancer microbiome

Spatial transcriptomics unveils landscape of resistance to concurrent chemo-radiotherapy in hypopharyngeal SCC — the role of SPP1+ macrophages